Type 1 diabetes (T1D) has a strong genetic component and the major locus lies in the HLA DQB1 region. We found earlier an increased apoptosis with decreased viability and function of the CD4 þ CD25 þ high T-cell subset (Treg) in human subjects with recent-onset T1D and in multiple autoantibody-positive, high at-risk individuals. Tregs normally inhibit or delay onset of T1D in animal models and increased Treg apoptosis could bring on or accelerate disease from effector T-cell-mediated destruction of insulin-producing beta cells. In this study, we test the hypothesis that HLA DQB1 genotypes are associated with increased CD4 þ CD25 þ high T-cell apoptosis. HLA DQ-based genetic risk status was significantly associated with CD4 þ CD25 þ high T-cell apoptosis, after adjustment for age, gender and phenotypic status (n ¼ 83, F ¼ 4.04 (d.f. ¼ 3), P ¼ 0.01). Unaffected, autoantibody-negative high risk HLA DQB1 control subjects showed increased CD4 þ CD25 þ high apoptosis levels compared with low risk HLA DQB1 control subjects (n ¼ 26, P ¼ 0.002), confirming that the association precedes disease. The association of specific HLA DQB1 genotypes with Treg apoptosis was also tested, showing significance for HLA DQB1*0302, DQB1*0201 and HLA DQB1*0602 alleles. Our study shows an association of HLA DQB1 genotypes with CD4 þ CD25 þ high T-cell apoptosis, which implicates CD4 þ CD25 þ high T-cell apoptosis as a new intermediate trait for T1D.
Introduction
Type 1 diabetes (T1D) is the result of T-cell-mediated destruction of insulin-producing b-cells in the pancreas, leading to a lifelong dependency on exogenous insulin. Susceptibility to this destructive process is a result of a complex interaction between genetic and environmental factors. 1, 2 Numerous adoptive transfer studies in animal models (NOD mice and BB rat) indicate that both CD4 þ and CD8 þ T cells are involved in the pathogenesis of T1D. [3] [4] [5] [6] [7] [8] In the pancreatic infiltrate (insulitis), both autoaggressive T cells (CD4 þ and CD8 þ ) and regulatory T cells (CD4 þ CD25 þ high T-cell or Tregs) with suppressive function are present. 9 The activation of these T cells is restricted by proteins encoded by genes in the human leukocyte antigen (HLA) region. The primary function of these HLA classes I and II protein molecules is to present protein-derived antigen fragments to CD8 þ and CD4 þ T-cells, respectively. Sequence changes in HLA genes could cause disruption of either central or peripheral tolerance, which can result in the predominance of islet-specific, autoaggressive T cells in the periphery, [10] [11] [12] which can lead to autoimmunity. 13 As both CD4 þ and CD8 þ T cells are involved in the pathogenesis of T1D, the importance of HLA classes I and II molecules is underlined. Even though CD8 þ T cells are probably the final mediators, the dominant role for CD4 þ T cells in the development of T1D is accepted, as two major isotypes of HLA class II molecules, DQ and DR, show a strong primary association with susceptibility or resistance to the disease. [14] [15] [16] Among these, HLA DQB1 has been shown to be the most important T1D risk factor, with HLA DQA1 and HLA DRB1 modulating the impact that specific HLA DQB1 alleles exert on disease predisposition. 17 A few studies have reported decreased regulatory function of CD4 þ CD25 þ high T cells in pediatric subjects with T1D. [18] [19] [20] Our group has also recently reported increased apoptosis of CD4 þ CD25 þ high T cells in recent-onset T1D subjects (in the 'honeymoon' phase) as well as in multiple autoantibody-positive individuals, but not in long-standing T1D subjects. 19 The strong association of HLA DQB1 genes with T1D and the increased apoptosis of CD4 þ CD25 þ high T cells in T1D subjects led us to investigate whether there is an association between HLA DQB1 and CD4 þ CD25 þ high T-cell apoptosis. Indeed, we show such an association, irrespective of the immune status.
Results
CD4 þ T-cell sorting and purity of isolated T-cell subsets A fluorescent-activated cell sorter (FACS) isolation method was used for cell separation in subjects recruited for this study whose demographic data are presented in Table 1 . The FACS method enabled the isolation of pure T-cell subsets from a heterogeneous T-cell mixture. Given that there is no unique Treg surface marker, the purity of isolated CD4 þ CD25 þ high T cells was maximized by a multistep isolation strategy ( Figure 1a ). As shown, three cell subsets known as unactivated (CD4 þ CD25À), activated (CD4 þ CD25 þ low ) and regulatory (CD4 þ CD25 þ high ) T cells were isolated from each subject. In this study, CD4 þ CD25 þ high T cells have high levels of intracellular FoxP3, have no or reduced expression of CD127 and are easily induced to die on deprivation of IL-2. Control, long-standing T1D and single autoantibody-positive subjects did not show significant differences in apoptosis levels across the three cell subsets (Figure 1b , traditional repeated measures ANOVA, 21 P ¼ 0.067, P ¼ 0.077 and P ¼ 0.74, respectively). However, there was significantly higher apoptosis level of CD4 þ CD25 þ high T-cell population in subjects with recent-onset T1D and multiple autoantibody-positive subjects, compared with the other two T-cell subsets (mean square or MS ¼ 556.1
þ high T-cell apoptosis levels and decreased function in subjects with recent onset of T1D Given that there is no unique Treg surface marker, the CD4 þ CD25 þ high T-cell subset is certain to contain activated T cells as well. Therefore, FACS-isolated CD4 þ CD25 þ high T cells were tested for their suppressive function using our standardized in vitro suppression assays (Figure 2a ). Proliferation of CD4 þ CD25À T cells in co-culture with CD4 þ CD25 þ high T cells at a high ratio of 10:1 measured the potency of regulatory T cells among CD4 þ CD25 þ high T cells, as well as verifying that the isolation of a relatively pure population was achieved. There was a significant difference in suppressive potential between the studied groups (KruskalWallis test, P ¼ 0.0003). Compared with control subjects, recent-onset T1D and multiple autoantibody subjects showed significant decrease in suppressive function (Po0.001 and Po0.01, respectively). Levels of apoptosis and death of CD4 þ CD25 þ high T cells measured with the same assay (both YOPRO1 þ ve and 7AAD þ ve), negatively correlated with the suppressive function (Spearman's rank correlation coefficient r ¼ À0.49, Po0.0001; Figure 2b ), suggesting that apoptosis contributed to their impaired function.
HLA DQB1 and CD4 þ CD25 þ high T-cell apoptosis Testing specific HLA DQB1 genotypes in a moderately sized dataset used in this study would result in sparse data for most genotypes, and therefore would lead to spurious conclusions. To circumvent this problem, we modified HLA DQ haplogenotype-based risk scheme, initially developed by Dr William Hagopian, 22 to divide HLA DQ haplotypes with similar risk assignments into groups. The scheme then partitions HLA DQ genotypes into four groups optimized in a larger case/ control cohort, in which assignments for low (L), moderate (M), high (H) and very high (VH) risk were coded and used in regression analysis (see Supplementary Table 1 ).
After applying the HLA DQ-based risk to all subjects, we report that risk groups showed significantly different CD4 þ CD25 þ high T-cell apoptosis levels ( Figure 3a , Kruskal-Wallis test, P ¼ 0.0014). Subjects with very high HLA DQ risk assignment showed the highest CD4 þ CD25 þ high T-cell apoptosis levels, regardless of the disease status. Multivariate linear regression using percentage of CD4 þ CD25 þ high T-cell apoptosis as the dependent variable confirmed the statistical effect of HLA DQB1 and CD4 þ CD25 þ high T-cell apoptosis S Glisic et al HLA DQ region on CD4 þ CD25 þ high T-cell apoptosis. When all subjects were considered (n ¼ 83), we found that the HLA DQ risk was significantly associated with
P ¼ 0.01), even when controlled for age, gender and phenotypic status. To enhance power, only two extreme groups were tested further. Healthy control (n ¼ 26) and recent-onset T1D (n ¼ 20) subjects were separated on low (b) Apoptosis differences of three FACS-isolated T-cell subsets in separate subject groups using YOPRO1/7AAD method. Only recent-onset T1D and multiple autoantibody-positive subjects showed a significant difference in apoptosis between cell subsets (Po0.0001 and P ¼ 0.0037, respectively).
Figure 2
In vitro suppression assay confirmed functional defect of CD4 þ CD25 þ high T cells in subjects with T1D. (a) in vitro suppression assay with 1:10 ratio was designed to test not only the function of isolated CD4 þ CD25 þ high T cells, but their purity as well. Tukey test showed statistically significant difference between control and recent-onset T1D subjects, as well as between control and multiple autoantibody-positive unaffected subjects (Po0.001 and Po0.01, respectively). (b) High suppression was correlated with low CD4 þ CD25 þ high T-cell apoptosis þ death and vice versa (Spearman rank correlation coefficient r ¼ À0.49; Po0.0001).
and M-H-VH HLA DQ risk. A statistically significant step-wise increase of CD4 þ CD25 þ high T-cell apoptosis was observed (Figure 3b ; Kruskal-Wallis test, Po0.0001). Normoglycemic control subjects with M-H-VH HLA DQ risk showed higher CD4 þ CD25 þ high T-cell apoptosis compared with low risk HLA DQ control subjects (Figure 3b ; P ¼ 0.027). This suggests a separate effect the HLA DQ locus has on CD4 þ CD25 þ high T-cell apoptosis that is independent of the disease. This effect in control subjects was confirmed using multivariate regression after adjusting for age and gender (P ¼ 0.002). In the recent-onset T1D group, both low and M-H-VH HLA DQ risk showed higher apoptosis levels than control M-H-VH HLA DQ risk subjects. When compared with control subjects, CD4 þ CD25 þ high T-cell apoptosis was significantly higher in M-H-VH recent-onset T1D subjects (Po0.0001). This suggests that the disease status has an additional effect on CD4 þ CD25 þ high T-cell apoptosis.
HLA DQB1 genotypes and CD4 þ CD25 þ high T-cell apoptosis As the next step in studying the effect that HLA DQ locus might have on apoptosis of CD4 þ CD25 þ high T-cells, we focused on an association between different HLA DQB1 genotypes and elevated levels of CD4 þ CD25 þ high T-cell apoptosis. Our relatively small group of subjects limited our work to an association of CD4 þ CD25 þ high T-cell apoptosis with the most frequent HLA DQB1 alleles in a population. 23 Subjects were grouped according to the presence of HLA DQB1*0302, HLA DQB1*0201, HLA DQB1*0602, HLA DQB1*0202, HLA DQB1*0301 and HLA DQB1*0501 genotypes and their CD4 þ CD25 þ high T-cell apoptosis levels were compared (Figure 4 presents only genotypes giving significant difference in CD4 þ CD25 þ high T-cell apoptosis). Clearly, when all the 83 participants were included, subjects with one copy of the susceptible HLA DQB1*0302 and HLA DQB1*0201 alleles had increased levels of CD4 þ CD25 þ high T-cell apoptosis (Figures 4a and b ; Po0.0001 and P ¼ 0.013, respectively). In contrast, the presence of the HLA DQB1*0602 genotype was associated with lower apoptosis levels (Figure 4c ; P ¼ 0.03). HLA DQB1*0202, HLA DQB1*0301 and HLA DQB1*0501 genotypes were not associated with increased CD4 þ CD25 þ high T-cell apoptosis (graphs not shown, P ¼ 0.889, P ¼ 0.234 and P ¼ 0.869, respectively). high T-cell apoptosis with HLA DQB1 genotypes. Healthy control and recent-onset T1D subjects were selected and the association between CD4 þ CD25 þ high T-cell apoptosis and two susceptible HLA DQB1 alleles (HLA DQB1*0302 and HLA DQB1*0201) or one protective allele (HLA DQB1*0602) were tested. (a) Heterozygotes for susceptible alleles HLA DQB1*0302 showed significantly higher CD4 þ CD25 þ high T-cell apoptosis levels compared with homozygotes x/x and HLA DQB1*0302/*0302 (Po0.0001) (b) Heterozygotes for susceptible alleles HLA DQB1*0201 showed significantly higher CD4 þ CD25 þ high T-cell apoptosis levels compared with homozygotes y/y and HLA DQB1*0201/*0201 (P ¼ 0.013). (c) The presence of T1D protective HLA DQB1*0602 allele was associated with lower CD4 þ CD25 þ high T-cells apoptosis levels (P ¼ 0.03). 'x' represents any non-HLA DQB1*0302 allele; 'y' represents any non-HLA DQB1*0201 allele and 'z' represents any non-HLA DQB1*0602 allele. Although the groups were small, we show the trend that is consistent with the statistically significant result.
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Discussion
Careful isolation of T-cell subsets via a FACS sorting strategy using the Fluorochrome Minus One method has enabled the separation of highly pure cell populations with distinct apoptotic and suppressive characteristics. It has been reported that FACS isolation of about 2% of CD4 þ CD25 þ high T-cells results in highly functional regulatory T cells. 24 However, subjects with active autoimmune disease are more likely to have a higher frequency of activated T cells than healthy control subjects. [25] [26] [27] Therefore, we designed a FACS isolation strategy in which non-CD4 þ T cells were eliminated and only the top 1% of CD4 þ CD25 þ high T cells were collected as the regulatory T-cell subset. We have reported elevated apoptosis levels and decreased function of the CD4 þ CD25 þ high T-cell subset isolated from subjects with recent-onset T1D and from multiple autoantibody-positive subjects. 19 We have also shown that elevated Treg apoptosis does not result from hyperglycemia. 19 Other studies have also noticed impaired Treg function in subjects with T1D. 18, 20 In this study, increased apoptosis and death of CD4 þ CD25 þ high T cells showed a highly significant (negative) correlation with decreased suppressive potential, when all subjects were analyzed. It remains unclear, however, if apoptosis and consequential decrease in function of CD4 þ CD25 þ high T cells are the cause of deliberated autoimmune attack of pancreatic b-cells or a result of the disease process. The effect of the immune status on CD4 þ CD25 þ high T-cell apoptosis variation was confirmed by a multivariate regression analysis. This result was seen in earlier studies. 19, 28 However, despite this, there was still a significant impact of HLA DQ risk status on variation of CD4 þ CD25 þ high T-cell apoptosis. Association of the HLA region to T1D has been described in many studies. 8, 14, [29] [30] [31] [32] Earlier studies derived a HLA DR-DQ haplotype-based risk strategy, which showed a statistically significant risk hierarchy, ranging from highly predisposing to highly protective. 33, 34 The need for at least three HLA DQ-DRbased risk groups was noticed by other groups, as well. 31, 35, 36 As this study focused exclusively on the HLA DQ region, which shows a high density of polymorphisms, a grouping based only on HLA DQ risk status was applied (see Supplementary data). The fact that high risk HLA DQB1 genotypes showed association with increased CD4 þ CD25 þ high T-cell apoptosis levels in control subjects suggests that increased CD4 þ CD25 þ high T-cell apoptosis is an intermediate trait and unlikely to be due to the diabetes itself.
In the future, we will work on improving the HLA DQ risk scheme, by including four-digit HLA DR and HLA class I genotypes and collecting a larger cohort. This will lead to a better understanding of the localization and association of any etiological variant with increased CD4 þ CD25 þ high T-cell apoptosis levels and T1D. In conclusion, our results indicate that subjects heterozygous for HLA DQB1*0302 and DQB1*0201 alleles are predisposed for elevated CD4 þ CD25 þ high T-cell apoptosis, regardless of the disease status. This HLA-risk driven increase in CD4 þ CD25 þ high T-cell apoptosis contributes to impaired function of regulatory T cells among CD4 þ CD25 þ high T cells, which then contributes to T1D development.
Research design and methods Eighty-three Wisconsin study subjects (76 Caucasian, 4 Asian, 1 African-American and 2 others) of both genders (38 females and 45 males) were recruited through the diabetes clinics at Children's Hospital of Wisconsin, Froedtert Hospital through ascertainment of a proband with the T1D onset before age of 17. Control subjects volunteered when visiting orthopedic, dental and eye clinics. Inclusion criteria for control subjects were random blood glucose o110 mg dl
À1
, no history of T1D or any autoimmune disorder in the family and an absence of T1D-specific autoantibodies. Healthy subjects of all ages were included (n ¼ 26). Autoantibody-positive, at-risk subjects (n ¼ 17) were first-degree relatives of T1D patients but were unrelated to the specific probands included in this study. T1D subjects were defined according to the accepted criteria: high blood glucose levels (X200 mg dl À1 ) with symptoms of diabetes confirmed by a physician. Recent-onset T1D subjects (n ¼ 20) were recruited after metabolic stabilization and within the first 10 months of diagnosis. Long-standing T1D subjects (n ¼ 20) were recruited at least 2 years after disease onset. Random glucose levels at the time of recruitment in long-standing T1D subjects were at comparable levels to the glucose levels measured in recent-onset T1D subjects (Table 1 ). All participants or their parents (guardians) provided written informed consent and completed a questionnaire. Autoantibodies and glucose levels were measured in all subjects at the recruitment visit. Recent-onset and long-standing T1D subjects had HbA1c and insulin dosage recorded as well (see Table 1 ).
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were collected using vacutainers with ACD solution B of trisodium citrate and isolation was done using FicollHypaque density gradient centrifugation following the manufacturer's protocol (Amersham Pharmacia, Uppsala, Sweden). Cells were counted using trypan blue exclusion test and a haemocytometer. Before FACS isolation was applied, cells were stained with a cocktail of fluorochrome-conjugated monoclonal antibodies in PBS (APC-aCD4 (clone RPA-T4), APC-Cy7-aCD25 (clone M-A251), FITC-aCD14 (clone M5E2), FITC-aCD32 (clone FLI8.26), FITC-aCD116 (clone M5D12), PE-Cy7-aCD8 (clone RPA-T8) (all from BD Pharmingen, San Diego, CA, USA) and sorted on FACSAria (BD Biosciences, San Diego, CA, USA). Cells were gated first for live lymphocytes, eliminating dead cells and debris (P1 in Figure 1a) . The next two gates were set up to eliminate non-CD4T cells (FITC-and PECy7-conjugated antibodies; one of these gates, P3, is presented in Figure 1a ). CD4 þ T cells were further gated as CD4 þ CD25À and CD4 þ CD25 þ using the Fluorochrome Minus One (FMO) method that allows a more precise definition of cells having fluorescence above the background level. 37 The 1% of cells expressing the highest level of CD25 were collected from each subject throughout clinical groups and defined as CD4 þ CD25 þ high T cells, known to be enriched for Tregs. 38 These cells showed the anticipated distribution of non-unique surface markers expected for CD4 þ CD25 þ high T cells (data not shown).
Apoptosis measurement
Apoptosis in all samples was measured using our recently published method. 39 Briefly, cells were stained with YOPRO1 (125 nM, Molecular Probes, Eugene, OR, USA) for 20 min in the dark and 7AAD (250 ng, BD Biosciences, San Diego, CA, USA) was added 10 min before acquiring events. Apoptosis was measured as the percentage of apoptotic cells (YOPRO1 þ ve/7AADÀve) among live cells (total 7AADÀve cells comprising both YOPRO1 þ ve and YOPRO1Àve cells). Dead cells were calculated as percentage of 7AAD þ ve/YOPRO1Àve cells plus percentage of 7AAD þ ve/YOPRO1 þ ve T cells among total cells.
Functional (suppression) assay
The only reliable feature of regulatory fraction among CD4 þ CD25 þ high T cells is their capacity to suppress proliferation of responder T cells. This capacity was measured via an in vitro proliferation assay, in which responder (CD4 þ CD25À) and regulatory T cells (CD4 þ CD25 þ high ) were stimulated separately and together in co-culture under defined conditions. The proliferation assay was performed using 25 000 responder T cells (CD4 þ CD25À) and 25 000 irradiated PBMCs (5000 rad) alone and together with 2500 CD4 þ CD25 þ HLA DQ genotyping All subjects were genotyped at HLA DQA1 and HLA DQB1 by direct sequencing. For each gene, exon 2 was sequenced using either Big Dye v3.1 sequencing chemistry (Applied Biosystems, Foster City, CA, USA) or Secore DQB1 locus sequencing kits [Dynal (Invitrogen), Brown Deer, WI, USA]. This method yields two-digit resolution of HLA DQA1 and four-digit resolution of HLA DQB1. To infer HLA DQA1 and HLA DQA1-DQB1 haplotypes, published Caucasian haplotype frequencies were used. 23 All sequencing reads were performed on either an ABI Prism 3700 or 3730 Â l DNA analyzer (Applied Biosystems).
Statistics
The Kruskal-Wallis and Mann-Whitney tests were used for clinical groups comparisons, with P value p0.05 considered statistically significant. Comparison of T-cell apoptosis in three cell types isolated from each subject (that are, therefore, correlated) was done using traditional repeated measures ANOVA. Before using our HLA DQ risk scheme, we tested its performance in capturing HLA DQ-associated risk for T1D, where the scheme proved to be effective in prediction of affection status (Supplementary file). Multivariate linear regression was used to evaluate the effect of the HLA DQB1 locus on CD4 þ CD25 þ high T-cell apoptosis, while controlling for other potentially confounding factors. Age and gender were included in the regression model as covariates, and phenotypic group assignment (that is, recent-onset T1D subjects, long-standing T1D subjects, single autoantibody-positive subjects, multiple autoantibody-positive subjects and control subjects) was included as a categorical variable. The effects of the HLA DQB1 locus were included as a four-value covariate for HLA risk determined as mentioned earlier (labeled as low, moderate, high and very high risk groups). The statistical analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC, USA). GraphPad software was used for data presentation.
